---
title: "Psych News Alert: Three-Month Form of Paliperidone Reduces Relapse in Schizophrenia, Study Shows"
description: A three-month formulation of paliperidone palmitate administered four times yearly as a long-acting injectable significantly delayed time...
image: https://alert.psychnews.org/hubfs/Imported_Blog_Media/shutterstock_182778842-Jun-24-2025-05-25-14-9791-PM.jpg
---

 3/31/15 12:00 AM

# Three-Month Form of Paliperidone Reduces Relapse in Schizophrenia, Study Shows

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [ Psychiatric News Alert ](https://alert.psychnews.org/author/psychiatric-news-alert)

Share: [facebook-f icon ](http://www.facebook.com/share.php?u=https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html) [linkedin-in icon ](http://www.linkedin.com/shareArticle?mini=true&url=https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html) [Twitter icon ](https://twitter.com/intent/tweet?url=https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html) [pinterest-p icon ](http://pinterest.com/pin/create/link/?url=https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html) [envelope icon ](mailto:?body=https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html)

| ![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/shutterstock_182778842-Jun-24-2025-05-25-14-1950-PM.jpg?width=200&height=200&name=shutterstock_182778842-Jun-24-2025-05-25-14-1950-PM.jpg) |  |
| --- | --- |

A three-month formulation of paliperidone palmitate administered four times yearly as a long-acting injectable significantly delayed time to relapse in patients with schizophrenia compared with placebo, according to a [report](http://archpsyc.jamanetwork.com/article.aspx?articleid=2211343) in *JAMA Psychiatry*.

Researchers with Janssen Research & Development LLC conducted a randomized, multicenter trial from April 2012 through April 2014 in eight countries. Of the 506 patients enrolled (aged 18 to 70 years; *DSM-IV-TR* diagnosis of schizophrenia), 305 were randomized to three-month paliperidone palmitate (n=160) or placebo (n=145).

A total of 42 patients (29 percent) in the placebo group and 14 patients (9 percent) in the group receiving three-month paliperidone palmitate experienced a relapse event. Consequently, the independent data-monitoring committee recommended early study termination for efficacy.

Paliperidone palmitate was originally formulated as a once-monthly atypical antipsychotic long-acting-injectable (LAI) and is approved for treatment of schizophrenia in adults in numerous countries. The recently developed three-month formulation offers the prospect of reducing relapse risk related to sub-therapeutic plasma concentrations and its associated negative consequences in patients with schizophrenia, the researchers noted.

“Patients randomly assigned to placebo were nearly four times more likely to relapse … than those who continued to receive three-month paliperidone palmitate,” they stated. “Patients at risk for sudden discontinuation from treatment could therefore benefit from three-month paliperidone palmitate, providing protection from relapse for up to one year after the last dose.”

For more on this topic, see the *Psychiatric News* article “[Some Experts Urge More Use of Long-Acting, Injectable Antipsychotics](http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2014.12a8).”

(Image: molekuul.be/shutterstock.com)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [long-acting injectable](https://alert.psychnews.org/tag/long-acting-injectable), [relapse](https://alert.psychnews.org/tag/relapse), [JAMA Psychiatry](https://alert.psychnews.org/tag/jama-psychiatry), [Paliperidone palmitate](https://alert.psychnews.org/tag/paliperidone-palmitate)

## Related posts

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/LIA%20Injectable-Jun-24-2025-10-23-12-8394-PM.jpg?height=200&name=LIA%20Injectable-Jun-24-2025-10-23-12-8394-PM.jpg) ](https://alert.psychnews.org/2015/06/long-acting-injectable-risperidone.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [long-acting injectable](https://alert.psychnews.org/tag/long-acting-injectable), [risperidone](https://alert.psychnews.org/tag/risperidone), [antipsychotic medication](https://alert.psychnews.org/tag/antipsychotic-medication)

## [Long-Acting Injectable Risperidone Leads to Greater Adherence, Relapse Prevention in Patients With Schizophrenia](https://alert.psychnews.org/2015/06/long-acting-injectable-risperidone.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 6/29/15 12:00 AM

Patients with a recent first episode of schizophrenia who are treated with a long-acting injectable...

[ Read more ](https://alert.psychnews.org/2015/06/long-acting-injectable-risperidone.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/syringe_vials_79412293-Jun-24-2025-09-48-28-3660-PM.jpg?height=200&name=syringe_vials_79412293-Jun-24-2025-09-48-28-3660-PM.jpg) ](https://alert.psychnews.org/2016/07/lai-antipsychotics-may-reduce.html)

[schizophrenia](https://alert.psychnews.org/tag/schizophrenia), [long-acting injectable](https://alert.psychnews.org/tag/long-acting-injectable), [antipsychotics](https://alert.psychnews.org/tag/antipsychotics), [Psychiatric Services in Advance](https://alert.psychnews.org/tag/psychiatric-services-in-advance), [rehospitalization](https://alert.psychnews.org/tag/rehospitalization)

## [LAI Antipsychotics May Reduce Rehospitalization of Patients With Schizophrenia](https://alert.psychnews.org/2016/07/lai-antipsychotics-may-reduce.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 7/20/16 12:00 AM

Patients with schizophrenia who receive a long-acting injectable (LAI) formulation as the first...

[ Read more ](https://alert.psychnews.org/2016/07/lai-antipsychotics-may-reduce.html)

[![](https://alert.psychnews.org/hs-fs/hubfs/Imported_Blog_Media/iStock-483968360-4.jpg?height=200&name=iStock-483968360-4.jpg) ](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

[aripiprazole](https://alert.psychnews.org/tag/aripiprazole), [bipolar disorder](https://alert.psychnews.org/tag/bipolar-disorder), [long-acting injectable antipsychotics](https://alert.psychnews.org/tag/long-acting-injectable-antipsychotics)

## [LAI Aripiprazole May Reduce Recurrence of Mood Episodes in Patients With Bipolar I Disorder](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

![Picture of Psychiatric News Alert](https://alert.psychnews.org/hs-fs/hubfs/Psych%20News%20Email%20Banners/PN-Blue-Box_rgb.png?width=50&name=PN-Blue-Box_rgb.png) [Psychiatric News Alert](https://alert.psychnews.org/author/psychiatric-news-alert) 

 2/1/17 12:00 AM

Treating patients with bipolar I disorder with a once-monthly long-acting injectable (LAI) form of...

[ Read more ](https://alert.psychnews.org/2017/02/lai-aripiprazole-may-reduce-recurrence.html)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Psychiatric News Alert",
    "url" : "https://alert.psychnews.org/author/psychiatric-news-alert"
  },
  "dateModified" : "2025-06-24T17:30:02.239Z",
  "datePublished" : "2015-03-31T04:00:00.000Z",
  "headline" : "Psych News Alert: Three-Month Form of Paliperidone Reduces Relapse in Schizophrenia, Study Shows",
  "image" : [ "https://alert.psychnews.org/hubfs/Imported_Blog_Media/shutterstock_182778842-Jun-24-2025-05-25-14-9791-PM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://alert.psychnews.org/2015/03/three-month-form-of-paliperidone.html",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://alert.psychnews.org/hubfs/PN-Blue-Box.jpg"
    }
  }
}
```